Literature DB >> 12957269

Selective targeting of homologous DNA recombination repair by gemcitabine.

Floris M Wachters1, John W G van Putten, Jan G Maring, Malgorzata Z Zdzienicka, Harry J M Groen, Harm H Kampinga.   

Abstract

PURPOSE: Gemcitabine (2',2'-difluoro-2'-deoxycytidine, dFdC) is a potent radiosensitizer. The mechanism of dFdC-mediated radiosensitization is yet poorly understood. We recently excluded inhibition of DNA double-strand break (DSB) repair by nonhomologous end-joining (NHEJ) as a means of radiosensitization. In the current study, we addressed the possibility that dFdC might affect homologous recombination (HR)-mediated DSB repair or base excision repair (BER). METHODS AND MATERIALS: DFdC-mediated radiosensitization in cell lines deficient in BER and in HR was compared with that in their BER-proficient and HR-proficient parental counterparts. Sensitization to mitomycin C (MMC) was also investigated in cell lines deficient and proficient in HR. Additionally, the effect of dFdC on Rad51 foci formation after irradiation was studied.
RESULTS: DFdC did induce radiosensitization in BER-deficient cells; however, the respective mutant cells deficient in HR did not show dFdC-mediated radiosensitization. In HR-proficient, but not in HR-deficient, cells dFdC also induced substantial enhancement of the cytotoxic effect of MMC. Finally, we found that dFdC interferes with Rad51 foci formation after irradiation.
CONCLUSION: DFdC causes radiosensitization by specific interference with HR.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12957269     DOI: 10.1016/s0360-3016(03)00503-0

Source DB:  PubMed          Journal:  Int J Radiat Oncol Biol Phys        ISSN: 0360-3016            Impact factor:   7.038


  29 in total

1.  The human immunodeficiency virus protease inhibitor ritonavir inhibits lung cancer cells, in part, by inhibition of survivin.

Authors:  Anjaiah Srirangam; Monica Milani; Ranjana Mitra; Zhijun Guo; Mariangellys Rodriguez; Hitesh Kathuria; Seiji Fukuda; Anthony Rizzardi; Stephen Schmechel; David G Skalnik; Louis M Pelus; David A Potter
Journal:  J Thorac Oncol       Date:  2011-04       Impact factor: 15.609

Review 2.  The role of radiotherapy in locally advanced pancreatic carcinoma.

Authors:  Ruchika Gutt; Stanley L Liauw; Ralph R Weichselbaum
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2010-07-13       Impact factor: 46.802

3.  Mechanism of radiosensitization by the Chk1/2 inhibitor AZD7762 involves abrogation of the G2 checkpoint and inhibition of homologous recombinational DNA repair.

Authors:  Meredith A Morgan; Leslie A Parsels; Lili Zhao; Joshua D Parsels; Mary A Davis; Maria C Hassan; Sankari Arumugarajah; Linda Hylander-Gans; Deborah Morosini; Diane M Simeone; Christine E Canman; Daniel P Normolle; Sonya D Zabludoff; Jonathan Maybaum; Theodore S Lawrence
Journal:  Cancer Res       Date:  2010-05-25       Impact factor: 12.701

4.  Drug metabolism and homologous recombination repair in radiosensitization with gemcitabine.

Authors:  Michael M Im; Sheryl A Flanagan; Jeffrey J Ackroyd; Donna S Shewach
Journal:  Radiat Res       Date:  2015-01-07       Impact factor: 2.841

Review 5.  Combined Treatment Modalities for High-Energy Proton Irradiation: Exploiting Specific DNA Repair Dependencies.

Authors:  Simon Deycmar; Martin Pruschy
Journal:  Int J Part Ther       Date:  2018-09-21

6.  PEGylated squalenoyl-gemcitabine nanoparticles for the treatment of glioblastoma.

Authors:  Alice Gaudin; Eric Song; Amanda R King; Jennifer K Saucier-Sawyer; Ranjit Bindra; Didier Desmaële; Patrick Couvreur; W Mark Saltzman
Journal:  Biomaterials       Date:  2016-08-04       Impact factor: 12.479

Review 7.  Improving gemcitabine-mediated radiosensitization using molecularly targeted therapy: a review.

Authors:  Meredith A Morgan; Leslie A Parsels; Jonathan Maybaum; Theodore S Lawrence
Journal:  Clin Cancer Res       Date:  2008-11-01       Impact factor: 12.531

8.  In vitro study on the schedule-dependency of the interaction between pemetrexed, gemcitabine and irradiation in non-small cell lung cancer and head and neck cancer cells.

Authors:  An Wouters; Bea Pauwels; Filip Lardon; Greet G O Pattyn; Hilde A J Lambrechts; Marc Baay; Paul Meijnders; Jan B Vermorken
Journal:  BMC Cancer       Date:  2010-08-19       Impact factor: 4.430

9.  Sensitization of tumor to ²¹²Pb radioimmunotherapy by gemcitabine involves initial abrogation of G2 arrest and blocked DNA damage repair by interference with Rad51.

Authors:  Kwon Joong Yong; Diane E Milenic; Kwamena E Baidoo; Martin W Brechbiel
Journal:  Int J Radiat Oncol Biol Phys       Date:  2012-11-29       Impact factor: 7.038

10.  The role of apoptotic cell death in the radiosensitising effect of gemcitabine.

Authors:  B Pauwels; J B Vermorken; A Wouters; J Ides; S Van Laere; H A J Lambrechts; G G O Pattyn; K Vermeulen; P Meijnders; F Lardon
Journal:  Br J Cancer       Date:  2009-08-18       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.